Annual Consortium Meeting – Two Days of Collaboration and Progress !

The INVENTS consortium gathered for its annual two-days meeting at PariSanté Campus, Paris, on October 2nd and 3rd 2025, bringing together all partners to review progress, exchange ideas, and plan the next steps of the work.

The first day started with a discussion led by Kit Roes on the INVENTS collective response to the ICH E20 guidelines on adaptive designs for clinical trials. It was then followed by an opening presentation by Sarah Zohar, the project coordinator, who provided an overview of the project’s vision and key achievements so far. It then continued with the insightful presentations by members of WP3, WP4, WP5 and WP6, followed by engaging discussions.
The second day continued with presentations by members of WP1, WP2, WP7  and WP8, and ended with closing remarks by our coordinator, highlighting the key takeaways and future steps of the project. We were also honored to welcome Dusan Sandor, our EU project officer.

We would also like to extend our sincere thanks to the members of our Scientific Advisory Board (Frank Pétavy, Satoshi Morita, Martin Golebiewski) as well as Pr. Yuki Ando from PMDA, for their presence and constructive feedback on the project’s progress.

During this annual meeting, we also had the pleasure of welcoming Eric Sutherland, Senior Health Economist at EOCD, as a special guest speaker. He delivered a fascinating talk entitled: “When Hippocrates met AI: Scaling fast AND doing NO harm”, offering deep insights into how to use health data responsibly – minimizing potential harm to individuals while emphasizing the importance of operationalizing people, policy and processes.

The day before the official start of the consortium meeting, PhD students, postdocs, and other interested members had the opportunity to attend a dedicated training session on “Dose-finding”, delivered by Moreno Ursino, INVENTS member.
The session provided valuable insights and fostered stimulating discussions among early-career researchers within the consortium.